Dan Horner examines CRYOSTAT-2, a randomised trial of early empirical high-dose cryoprecipitate in major trauma haemorrhage. The appraisal explores the mortality results, trial limitations and subgroup findings, and considers what the study means for major haemorrhage protocols.